You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEscitalopram
Accession NumberDB01175  (APRD00683)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEscitalopram, the S-enantiomer of citalopram, belongs to a class of antidepressant agents known as selective serotonin-reuptake inhibitors (SSRIs). Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Chronic use leads to desensitization of somatodendritic 5-HT1A and terminal autoreceptors. The overall clinical effect of increased mood and decreased anxiety is thought to be due to adaptive changes in neuronal function that leads to enhanced serotonergic neurotransmission. Side effects include dry mouth, nausea, dizziness, drowsiness, sexual dysfunction and headache. Side effects generally occur within the first two weeks of therapy and are usually less severe and frequent than those observed with tricyclic antidepressants. Escitalopram may be used to treat major depressive disorder (MDD) and generalized anxiety disorder (GAD).
Structure
Thumb
Synonyms
(+)-Citalopram
(S)-Citalopram
Escitalopram Oxalate
Escitalopramum
Esertia
S-(+)-Citalopram
S(+)-Citalopram
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ach-escitalopramTablet10 mgOralAccord Healthcare Inc2016-06-10Not applicableCanada
Ach-escitalopramTablet20 mgOralAccord Healthcare Inc2016-06-10Not applicableCanada
Act EscitalopramTablet20 mgOralActavis Pharma Company2014-09-10Not applicableCanada
Act EscitalopramTablet5 mgOralActavis Pharma CompanyNot applicableNot applicableCanada
Act EscitalopramTablet10 mgOralActavis Pharma Company2014-09-10Not applicableCanada
Act Escitalopram ODTTablet, orally disintegrating10 mgOralActavis Pharma Company2016-08-17Not applicableCanada
Act Escitalopram ODTTablet, orally disintegrating20 mgOralActavis Pharma Company2016-08-17Not applicableCanada
Auro-escitalopramTablet5 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-escitalopramTablet15 mgOralAuro Pharma IncNot applicableNot applicableCanada
Auro-escitalopramTablet10 mgOralAuro Pharma Inc2014-09-10Not applicableCanada
Auro-escitalopramTablet20 mgOralAuro Pharma Inc2014-09-10Not applicableCanada
Cipralex -5mgTablet5 mgOralLundbeck Canada IncNot applicableNot applicableCanada
Cipralex -10mgTablet10 mgOralLundbeck Canada Inc2005-02-14Not applicableCanada
Cipralex -15mgTablet15 mgOralLundbeck Canada IncNot applicableNot applicableCanada
Cipralex -20mgTablet20 mgOralLundbeck Canada Inc2005-02-14Not applicableCanada
Cipralex MeltzTablet, orally disintegrating20 mgOralLundbeck Canada Inc2012-10-04Not applicableCanada
Cipralex MeltzTablet, orally disintegrating10 mgOralLundbeck Canada Inc2012-10-04Not applicableCanada
EscitalopramTablet10 mgOralSanis Health Inc2014-09-18Not applicableCanada
EscitalopramTablet10 mgOralSivem Pharmaceuticals Ulc2015-01-14Not applicableCanada
EscitalopramTablet20 mgOralSanis Health Inc2014-09-18Not applicableCanada
EscitalopramTablet20 mgOralSivem Pharmaceuticals Ulc2015-01-14Not applicableCanada
EscitalopramTablet10 mgOralPro Doc Limitee2014-09-15Not applicableCanada
EscitalopramTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
EscitalopramTablet20 mgOralPro Doc Limitee2014-09-15Not applicableCanada
EscitalopramTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Escitalopram OxalateTablet, film coated5 mg/1OralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralCardinal Health2002-08-14Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2016-02-11Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralMylan Institutional Inc.2012-02-29Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralCardinal Health2002-08-14Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2012-10-16Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralBlenheim Pharmacal, Inc.2016-02-11Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralMylan Pharmaceuticals Inc.2012-02-29Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralMylan Institutional Inc.2012-02-29Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralActavis Pharma, Inc.2015-04-01Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralPhysicians Total Care, Inc.2012-10-16Not applicableUs
Ipg-escitalopramTablet15 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-escitalopramTablet20 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-escitalopramTablet5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Ipg-escitalopramTablet10 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Jamp-escitalopramTablet10 mgOralJamp Pharma Corporation2014-09-11Not applicableCanada
Jamp-escitalopramTablet20 mgOralJamp Pharma Corporation2014-09-11Not applicableCanada
LexaproTablet20 mg/1OralCardinal Health2002-08-14Not applicableUs
LexaproTablet, film coated20 mg/1OralAidarex Pharmaceuticals LLC2002-08-14Not applicableUs
LexaproTablet20 mg/1OralPhysicians Total Care, Inc.2009-04-15Not applicableUs
LexaproTablet, film coated20 mg/1OralAllergan, Inc.2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralUnit Dose Services2002-08-14Not applicableUs
LexaproTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralSTAT Rx USA LLC2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralCardinal Health2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralAidarex Pharmaceuticals LLC2002-08-14Not applicableUs
LexaproTablet5 mg/1OralPhysicians Total Care, Inc.2009-11-30Not applicableUs
LexaproSolution5 mg/5mLOralAllergan, Inc.2002-11-26Not applicableUs
LexaproTablet, film coated5 mg/1OralSTAT Rx USA LLC2002-08-14Not applicableUs
LexaproTablet, film coated20 mg/1OralCardinal Health2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
LexaproTablet, film coated20 mg/1Oralbryant ranch prepack2002-08-14Not applicableUs
LexaproTablet, film coated5 mg/1OralAllergan, Inc.2002-08-14Not applicableUs
LexaproTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-03-182016-03-11Us
LexaproTablet10 mg/1OralCardinal Health2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2002-08-14Not applicableUs
LexaproTablet, film coated20 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
LexaproTablet, film coated10 mg/1Oralbryant ranch prepack2002-08-14Not applicableUs
LexaproTablet, film coated10 mg/1OralAllergan, Inc.2002-08-14Not applicableUs
LexaproTablet10 mg/1OralPhysicians Total Care, Inc.2005-12-28Not applicableUs
Mar-escitalopramTablet15 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mar-escitalopramTablet10 mgOralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-escitalopramTablet20 mgOralMarcan Pharmaceuticals Inc2014-09-10Not applicableCanada
Mar-escitalopramTablet5 mgOralMarcan Pharmaceuticals IncNot applicableNot applicableCanada
Mint-escitalopramTablet20 mgOralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mint-escitalopramTablet15 mgOralMint Pharmaceuticals IncNot applicableNot applicableCanada
Mint-escitalopramTablet10 mgOralMint Pharmaceuticals Inc2015-03-19Not applicableCanada
Mylan-escitalopramTablet10 mgOralMylan Pharmaceuticals Ulc2014-09-10Not applicableCanada
Mylan-escitalopramTablet20 mgOralMylan Pharmaceuticals Ulc2014-09-10Not applicableCanada
Nat-escitalopramTablet20 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
Nat-escitalopramTablet10 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
PMS-escitalopramTablet5 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-escitalopramTablet15 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-escitalopramTablet10 mgOralPharmascience Inc2014-09-10Not applicableCanada
PMS-escitalopramTablet20 mgOralPharmascience Inc2014-09-10Not applicableCanada
Priva-escitalopramTablet10 mgOralPharmapar Inc2014-09-10Not applicableCanada
Priva-escitalopramTablet20 mgOralPharmapar Inc2014-09-10Not applicableCanada
Ran-escitalopramTablet10 mgOralRanbaxy Pharmaceuticals Canada Inc.2014-09-10Not applicableCanada
Ran-escitalopramTablet20 mgOralRanbaxy Pharmaceuticals Canada Inc.2014-09-10Not applicableCanada
Riva-escitalopramTablet5 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-escitalopramTablet10 mgOralLaboratoire Riva Inc2014-09-25Not applicableCanada
Riva-escitalopramTablet15 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-escitalopramTablet20 mgOralLaboratoire Riva Inc2014-09-25Not applicableCanada
Sandoz EscitalopramTablet20 mgOralSandoz Canada Incorporated2014-09-10Not applicableCanada
Sandoz EscitalopramTablet10 mgOralSandoz Canada Incorporated2014-09-10Not applicableCanada
Teva-escitalopramTablet15 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Teva-escitalopramTablet10 mgOralTeva Canada Limited2014-09-10Not applicableCanada
Teva-escitalopramTablet20 mgOralTeva Canada Limited2014-09-10Not applicableCanada
Teva-escitalopramTablet5 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-escitalopramTablet10 mgOralApotex Inc2014-09-10Not applicableCanada
Apo-escitalopramTablet20 mgOralApotex Inc2014-09-10Not applicableCanada
EscitalopramTablet, film coated20 mg/1OralPreferred Pharmaceuticals, Inc.2014-09-25Not applicableUs
EscitalopramTablet, film coated20 mg/1OralInternational Laboratories, Inc.2013-09-20Not applicableUs
EscitalopramTablet, film coated20 mg/1OralRebel Distributors Corp2012-03-14Not applicableUs
EscitalopramTablet, film coated5 mg/1OralSTI Pharma LLC2013-09-12Not applicableUs
EscitalopramTablet, film coated10 mg/1OralSt. Marys Medical Park Pharmacy2016-04-01Not applicableUs
EscitalopramTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralUnit Dose Services2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-09-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralAmerican Health Packaging2013-07-01Not applicableUs
EscitalopramTablet, film coated20 mg/1OralSolco Healthcare US, LLC2012-03-15Not applicableUs
EscitalopramTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-05-02Not applicableUs
EscitalopramTablet, film coated5 mg/1OralREMEDYREPACK INC.2016-01-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralProficient Rx LP2012-03-14Not applicableUs
EscitalopramTablet, film coated5 mg/1OralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralCitron Pharma LLC2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralApotex Corp.2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-02-132016-10-13Us
EscitalopramTablet, film coated5 mg/1OralBlue Point Laboratories2014-02-06Not applicableUs
EscitalopramTablet, film coated10 mg/1OralUnit Dose Services2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralHikma Pharmaceutical2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralDispensing Solutions, Inc.2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralMc Kesson Contract Packaging2012-03-14Not applicableUs
EscitalopramTablet, film coated5 mg/1OralAccord Healthcare Inc.2013-01-15Not applicableUs
EscitalopramTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-09-052016-04-05Us
EscitalopramSolution5 mg/5mLOralMacleods Pharmaceuticals Limited2016-03-31Not applicableUs
EscitalopramTablet, film coated10 mg/1OralRebel Distributors Corp2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralReady Meds2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralA S Medication Solutions2013-03-19Not applicableUs
EscitalopramTablet, film coated10 mg/1OralInternational Laboratories, Inc.2013-09-19Not applicableUs
EscitalopramTablet5 mg/1OralCamber Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralSTI Pharma LLC2013-09-12Not applicableUs
EscitalopramTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
EscitalopramTablet, film coated5 mg/1OralAurobindo Pharma Limited2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2013-01-18Not applicableUs
EscitalopramTablet, film coated20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralREMEDYREPACK INC.2014-11-26Not applicableUs
EscitalopramTablet10 mg/1OralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
EscitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-05-08Not applicableUs
EscitalopramTablet5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-09-10Not applicableUs
EscitalopramTablet, film coated10 mg/1Oralbryant ranch prepack2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
EscitalopramTablet, film coated5 mg/1OralAvera Mc Kennan Hospital2015-03-16Not applicableUs
EscitalopramTablet, film coated20 mg/1OralSt. Mary's Medical Park Pharmacy2014-02-06Not applicableUs
EscitalopramTablet, film coated10 mg/1OralAidarex Pharmaceuticals LLC2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralUnit Dose Services2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralBlue Point Laboratories2014-02-06Not applicableUs
EscitalopramTablet, film coated20 mg/1OralUnit Dose Services2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralPreferred Pharmaceuticals, Inc.2016-10-25Not applicableUs
EscitalopramTablet, film coated5 mg/1OralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
EscitalopramTablet, film coated5 mg/1OralJubilant Cadista Pharmaceuticals Inc.2014-11-07Not applicableUs
EscitalopramTablet20 mg/1OralLegacy Pharmaceutical Packaging2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralAccord Healthcare Inc.2013-01-15Not applicableUs
EscitalopramTablet20 mg/1OralREMEDYREPACK INC.2014-02-282016-04-05Us
EscitalopramTablet, film coated20 mg/1OralSTAT Rx USA LLC2012-03-14Not applicableUs
EscitalopramTablet10 mg/1OralTYA Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2014-11-28Not applicableUs
EscitalopramTablet, film coated5 mg/1OralApotex Corp.2012-09-11Not applicableUs
EscitalopramTablet10 mg/1OralCamber Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralSTI Pharma LLC2013-09-12Not applicableUs
EscitalopramTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralAurobindo Pharma Limited2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2015-03-26Not applicableUs
EscitalopramTablet, film coated10 mg/1OralMajor Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated5 mg/1OralHikma Pharmaceutical2012-09-11Not applicableUs
EscitalopramTablet20 mg/1OralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
EscitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-05-28Not applicableUs
EscitalopramTablet10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-09-10Not applicableUs
EscitalopramTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-05-08Not applicableUs
EscitalopramTablet, film coated20 mg/1Oralbryant ranch prepack2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
EscitalopramTablet, film coated20 mg/1OralTeva Pharmaceuticals USA Inc2012-03-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralBlue Point Laboratories2014-02-06Not applicableUs
EscitalopramTablet, film coated10 mg/1OralPreferred Pharmaceuticals Inc.2016-12-05Not applicableUs
EscitalopramTablet, coated20 mg/1OralDIRECT RX2015-01-01Not applicableUs
EscitalopramTablet, film coated5 mg/1OralSolco Healthcare US, LLC2012-03-15Not applicableUs
EscitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2014-12-24Not applicableUs
EscitalopramTablet, film coated5 mg/1OralCitron Pharma LLC2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralPreferred Pharmaceuticals Inc.2016-06-09Not applicableUs
EscitalopramTablet, film coated10 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-09Not applicableUs
EscitalopramTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2012-03-14Not applicableUs
EscitalopramTablet20 mg/1OralTYA Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralUnit Dose Services2013-03-21Not applicableUs
EscitalopramTablet, film coated5 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralJubilant Cadista Pharmaceuticals Inc.2012-09-14Not applicableUs
EscitalopramTablet10 mg/1OralLegacy Pharmaceutical Packaging2012-09-11Not applicableUs
EscitalopramSolution5 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2012-05-03Not applicableUs
EscitalopramTablet, film coated20 mg/1OralAccord Healthcare Inc.2013-01-15Not applicableUs
EscitalopramTablet, film coated10 mg/1OralREMEDYREPACK INC.2015-03-09Not applicableUs
EscitalopramTablet, film coated10 mg/1OralApotex Corp.2012-09-11Not applicableUs
EscitalopramTablet20 mg/1OralCamber Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralCardinal Health2013-07-01Not applicableUs
EscitalopramTablet, film coated20 mg/1OralTYA Pharmaceuticals2013-03-21Not applicableUs
EscitalopramTablet, film coated10 mg/1OralREMEDYREPACK INC.2013-02-182016-10-13Us
EscitalopramTablet, film coated20 mg/1OralAurobindo Pharma Limited2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-03-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralMajor Pharmaceuticals2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralWest Ward Pharmaceuticals Corp2012-09-11Not applicableUs
EscitalopramTablet, film coated10 mg/1OralHikma Pharmaceutical2012-09-11Not applicableUs
EscitalopramTablet5 mg/1OralLupin Pharmaceuticals, Inc.2012-09-10Not applicableUs
EscitalopramTablet, film coated20 mg/1OralPd Rx Pharmaceuticals, Inc.2013-03-21Not applicableUs
EscitalopramTablet, film coated20 mg/1OralREMEDYREPACK INC.2013-09-042016-04-05Us
EscitalopramTablet20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2012-09-10Not applicableUs
EscitalopramTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-05-02Not applicableUs
EscitalopramTablet, film coated5 mg/1Oralbryant ranch prepack2012-03-14Not applicableUs
EscitalopramTablet, film coated20 mg/1OralA S Medication Solutions2013-03-21Not applicableUs
EscitalopramTablet, film coated10 mg/1OralCitron Pharma LLC2012-09-11Not applicableUs
EscitalopramTablet, film coated20 mg/1OralNorthwind Pharmaceuticals2014-03-21Not applicableUs
EscitalopramTablet, film coated10 mg/1OralAmerican Health Packaging2013-07-01Not applicableUs
EscitalopramTablet, film coated10 mg/1OralProficient Rx LP2012-03-14Not applicableUs
EscitalopramTablet, film coated10 mg/1OralSolco Healthcare US, LLC2012-03-15Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralAmneal Pharmaceuticals of New York, LLC2011-09-03Not applicableUs
Escitalopram OxalateTablet20 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/21OralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralCipla USA Inc.2016-06-16Not applicableUs
Escitalopram OxalateTablet10 mg/1OralMajor Pharmaceuticals2014-10-15Not applicableUs
Escitalopram OxalateTablet20 mg/1OralDIRECT RX2015-01-01Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralCamber Pharmaceuticals, Inc.2012-06-12Not applicableUs
Escitalopram OxalateTablet10 mg/1OralCardinal Health2014-10-15Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-06-16Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralLeading Pharma, Llc2015-08-01Not applicableUs
Escitalopram OxalateTablet10 mg/1OralREMEDYREPACK INC.2016-05-17Not applicableUs
Escitalopram OxalateTablet5 mg/1OralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/21OralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralCipla USA Inc.2016-06-16Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralCitron Pharma LLC2012-04-03Not applicableUs
Escitalopram OxalateTablet20 mg/1OralMajor Pharmaceuticals2014-10-15Not applicableUs
Escitalopram OxalateTablet10 mg/1OralDIRECT RX2015-01-01Not applicableUs
Escitalopram OxalateTablet, film coated20 mg/1OralLegacy Pharmaceutical Packaging, Llc2016-06-16Not applicableUs
Escitalopram OxalateTablet10 mg/1OralA S Medication Solutions2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated5 mg/1OralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram OxalateTablet10 mg/1OralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram OxalateTablet5 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram OxalateTablet20 mg/1OralAidarex Pharmaceuticals LLC2012-09-11Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralSilarx Pharmaceuticals, Inc2013-06-12Not applicableUs
Escitalopram OxalateTablet20 mg/1OralA S Medication Solutions2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated10 mg/1OralExelan Pharmaceuticals Inc.2012-10-01Not applicableUs
Escitalopram OxalateTablet20 mg/1OralTorrent Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated5 mg/1OralMacleods Pharmaceuticals Limited2012-09-11Not applicableUs
Escitalopram OxalateTablet, film coated5 mg/1OralCipla USA Inc.2016-06-16Not applicableUs
Escitalopram OxalateTablet10 mg/1OralBlenheim Pharmacal, Inc.2013-11-15Not applicableUs
Escitalopram OxalateSolution5 mg/5mLOralAurobindo Pharma Limited2012-04-03Not applicableUs
LexaproTablet10 mg/1OralDIRECT RX2016-05-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CipralexNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII4O4S742ANY
CAS number128196-01-0
WeightAverage: 324.3919
Monoisotopic: 324.163791509
Chemical FormulaC20H21FN2O
InChI KeyWSEQXVZVJXJVFP-FQEVSTJZSA-N
InChI
InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
IUPAC Name
(1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
SMILES
CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Pharmacology
IndicationLabeled indications include major depressive disorder (MDD) and generalized anxiety disorder (GAD). Unlabeled indications include treatment of mild dementia-associated agitation in nonpsychotic patients.
Structured Indications
PharmacodynamicsEscitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.
Mechanism of actionThe antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. Escitalopram blocks the reuptake of serotonin at the serotonin reuptake pump of the neuronal membrane, enhancing the actions of serotonin on 5HT1A autoreceptors. SSRIs bind with significantly less affinity to histamine, acetylcholine, and norepinephrine receptors than tricyclic antidepressant drugs.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
Sodium-dependent dopamine transporterProteinunknown
inhibitor
HumanQ01959 details
Sodium-dependent noradrenaline transporterProteinunknown
inhibitor
HumanP23975 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Related Articles
AbsorptionThe absolute bioavailability of citalopram is about 80% relative to an intravenous dose.
Volume of distribution
  • 12 L/kg
Protein binding~56%
Metabolism

Mainly hepatic. Escitalopram undergoes N-demethylation to S-demethylcitalopram (S-DCT) and S-didemethylcitalopram (S-DDCT). CYP3A4 and CYP2C19 are the enzymes responsible for this N-demethylation reaction.

Route of eliminationFollowing oral administrations of escitalopram, the fraction of drug recovered in the urine as escitalopram and S-demethylcitalopram (S-DCT) is about 8% and 10%, respectively. The oral clearance of escitalopram is 600 mL/min, with approximately 7% of that due to renal clearance. Escitalopram is metabolized to S-DCT and S-didemethylcitalopram (S-DDCT).
Half life27-32 hours
Clearance
  • oral cl=600 mL/min [Following oral administrations]
ToxicitySigns of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Escitalopram Action PathwayDrug actionSMP00425
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Sodium-dependent serotonin transporter
Gene symbol: SLC6A4
UniProt: P31645
rs25531 Not AvailableA alleleIncrease risk of side effects (ie. headaches)19272758
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when 1,1,1,2 Tetrafluoroethane is combined with Escitalopram.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Escitalopram.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the serotonergic activities of Escitalopram.Experimental
AbirateroneThe serum concentration of Escitalopram can be increased when it is combined with Abiraterone.Approved
AcarboseEscitalopram may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolEscitalopram may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Escitalopram.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Acetophenazine.Approved
Acetylsalicylic acidEscitalopram may increase the antiplatelet activities of Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Escitalopram.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Escitalopram.Approved, Investigational
AlbiglutideEscitalopram may increase the hypoglycemic activities of Albiglutide.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Escitalopram.Vet Approved
AlfentanilAlfentanil may increase the serotonergic activities of Escitalopram.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram.Approved, Vet Approved
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Escitalopram.Approved, Investigational
AlogliptinEscitalopram may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolAlphacetylmethadol may increase the serotonergic activities of Escitalopram.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Escitalopram.Approved, Illicit, Investigational
AmantadineAmantadine may increase the QTc-prolonging activities of Escitalopram.Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.Illicit, Withdrawn
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.Approved, Illicit
AmoxapineAmoxapine may increase the QTc-prolonging activities of Escitalopram.Approved
AmperozideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Amperozide.Experimental
AnagrelideAnagrelide may increase the QTc-prolonging activities of Escitalopram.Approved
ApomorphineApomorphine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
AprepitantThe serum concentration of Escitalopram can be increased when it is combined with Aprepitant.Approved, Investigational
ArformoterolArformoterol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ArmodafinilThe metabolism of Escitalopram can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ArtemetherEscitalopram may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Escitalopram.Approved
AsenapineEscitalopram may increase the QTc-prolonging activities of Asenapine.Approved
AtazanavirThe metabolism of Escitalopram can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Escitalopram.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Azaperone.Vet Approved
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Escitalopram.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Escitalopram.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.Illicit
BedaquilineBedaquiline may increase the QTc-prolonging activities of Escitalopram.Approved
BendroflumethiazideEscitalopram may increase the hyponatremic activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the serotonergic activities of Escitalopram.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Escitalopram.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Escitalopram.Approved
BetaxololThe metabolism of Escitalopram can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Escitalopram can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideBezitramide may increase the serotonergic activities of Escitalopram.Experimental, Illicit, Withdrawn
BifeprunoxThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bifeprunox.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Escitalopram.Investigational
BoceprevirThe serum concentration of Escitalopram can be decreased when it is combined with Boceprevir.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
BosentanThe serum concentration of Escitalopram can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Escitalopram is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Escitalopram.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Escitalopram.Approved, Investigational
BuprenorphineBuprenorphine may increase the serotonergic activities of Escitalopram.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Escitalopram can be decreased when combined with Bupropion.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Escitalopram.Approved
BuspironeBuspirone may increase the serotonergic activities of Escitalopram.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Escitalopram.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Escitalopram.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Escitalopram.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Escitalopram.Approved, Illicit
ButorphanolButorphanol may increase the serotonergic activities of Escitalopram.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Escitalopram.Approved
CanagliflozinEscitalopram may increase the hypoglycemic activities of Canagliflozin.Approved
CarbamazepineThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Escitalopram.Approved
CarfentanilCarfentanil may increase the serotonergic activities of Escitalopram.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.Approved
CaroxazoneCaroxazone may increase the serotonergic activities of Escitalopram.Withdrawn
CelecoxibEscitalopram may increase the antiplatelet activities of Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Escitalopram can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Escitalopram.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Escitalopram.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Escitalopram can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Escitalopram.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Escitalopram.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Escitalopram.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
ChlorothiazideEscitalopram may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram.Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
ChlorpropamideEscitalopram may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneEscitalopram may increase the hyponatremic activities of Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram.Approved
CholecalciferolThe metabolism of Escitalopram can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Escitalopram can be increased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Escitalopram can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram.Approved, Vet Approved
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Escitalopram.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Escitalopram.Approved
ClemastineThe metabolism of Escitalopram can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.Approved
ClobazamThe metabolism of Escitalopram can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Escitalopram.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Escitalopram.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.Approved, Illicit
ClotrimazoleThe metabolism of Escitalopram can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Escitalopram.Approved
CobicistatThe serum concentration of Escitalopram can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Escitalopram can be decreased when combined with Cocaine.Approved, Illicit
CodeineCodeine may increase the serotonergic activities of Escitalopram.Approved, Illicit
ConivaptanThe serum concentration of Escitalopram can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibCrizotinib may increase the QTc-prolonging activities of Escitalopram.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Escitalopram.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.Approved
CyclosporineThe metabolism of Escitalopram can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.Approved
DabrafenibThe serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.Approved
DapagliflozinEscitalopram may increase the hypoglycemic activities of Dapagliflozin.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Escitalopram is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.Investigational
DarifenacinThe metabolism of Escitalopram can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Escitalopram can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Escitalopram can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Escitalopram.Approved
DelavirdineThe metabolism of Escitalopram can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Escitalopram.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Escitalopram.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Escitalopram.Vet Approved
DexamethasoneThe serum concentration of Escitalopram can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Escitalopram.Approved, Vet Approved
DextromethorphanEscitalopram may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideDextromoramide may increase the serotonergic activities of Escitalopram.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the serotonergic activities of Escitalopram.Approved, Illicit, Withdrawn
DezocineDezocine may increase the serotonergic activities of Escitalopram.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Escitalopram.Approved, Illicit, Vet Approved
DicoumarolEscitalopram may increase the anticoagulant activities of Dicoumarol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Escitalopram.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the serotonergic activities of Escitalopram.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Escitalopram.Approved
DihydroetorphineDihydroetorphine may increase the serotonergic activities of Escitalopram.Experimental, Illicit
DihydromorphineDihydromorphine may increase the serotonergic activities of Escitalopram.Experimental, Illicit
DiltiazemThe metabolism of Escitalopram can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Escitalopram.Approved
DiphenoxylateDiphenoxylate may increase the serotonergic activities of Escitalopram.Approved, Illicit
DisopyramideDisopyramide may increase the QTc-prolonging activities of Escitalopram.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Escitalopram.Approved
DolasetronDolasetron may increase the QTc-prolonging activities of Escitalopram.Approved
DomperidoneEscitalopram may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Escitalopram.Vet Approved
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Escitalopram.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.Approved
DoxycyclineThe metabolism of Escitalopram can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram.Approved, Vet Approved
DPDPEDPDPE may increase the serotonergic activities of Escitalopram.Investigational
DronedaroneEscitalopram may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Escitalopram.Experimental, Illicit
DulaglutideEscitalopram may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Escitalopram.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Escitalopram.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Escitalopram.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Escitalopram can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Escitalopram.Approved, Investigational
EliglustatEscitalopram may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinEscitalopram may increase the hypoglycemic activities of Empagliflozin.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Escitalopram.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.Approved, Investigational
EnzalutamideThe serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Escitalopram.Approved
EribulinEribulin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Escitalopram can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Escitalopram.Investigational
EsomeprazoleThe metabolism of Escitalopram can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Escitalopram.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Escitalopram.Approved
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.Approved
Ethyl biscoumacetateEscitalopram may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Escitalopram.Approved, Illicit
EthylmorphineEthylmorphine may increase the serotonergic activities of Escitalopram.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Escitalopram.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Escitalopram.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Escitalopram.Approved
EtodolacEscitalopram may increase the antiplatelet activities of Etodolac.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.Approved
EtoperidoneEscitalopram may increase the serotonergic activities of Etoperidone.Approved
EtoricoxibEscitalopram may increase the antiplatelet activities of Etoricoxib.Approved, Investigational
EtorphineEtorphine may increase the serotonergic activities of Escitalopram.Illicit, Vet Approved
EtravirineThe serum concentration of Escitalopram can be decreased when it is combined with Etravirine.Approved
ExenatideEscitalopram may increase the hypoglycemic activities of Exenatide.Approved, Investigational
EzogabineEzogabine may increase the QTc-prolonging activities of Escitalopram.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Escitalopram.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Escitalopram.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineEscitalopram may increase the serotonergic activities of Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Escitalopram.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Escitalopram.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Escitalopram.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Escitalopram.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Escitalopram.Approved, Illicit
FluindioneEscitalopram may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Escitalopram.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.Approved, Illicit
FluoxetineFluoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
FlupentixolFlupentixol may increase the QTc-prolonging activities of Escitalopram.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Escitalopram.Approved
FluvoxamineThe metabolism of Escitalopram can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
FosamprenavirThe metabolism of Escitalopram can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Escitalopram can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Escitalopram.Approved
FosphenytoinThe metabolism of Escitalopram can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Escitalopram.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Escitalopram.Approved, Investigational
FurazolidoneFurazolidone may increase the serotonergic activities of Escitalopram.Approved, Vet Approved
Fusidic AcidThe serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when gabapentin enacarbil is combined with Escitalopram.Approved
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Escitalopram.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Escitalopram.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Escitalopram.Approved, Illicit
GemfibrozilThe metabolism of Escitalopram can be decreased when combined with Gemfibrozil.Approved
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Escitalopram.Investigational
GliclazideEscitalopram may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEscitalopram may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEscitalopram may increase the hypoglycemic activities of Glipizide.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Escitalopram.Approved, Illicit
GlyburideEscitalopram may increase the hypoglycemic activities of Glyburide.Approved
GoserelinGoserelin may increase the QTc-prolonging activities of Escitalopram.Approved
GranisetronGranisetron may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Escitalopram.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the QTc-prolonging activities of Escitalopram.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.Approved, Vet Approved
HeroinHeroin may increase the serotonergic activities of Escitalopram.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Escitalopram.Approved
HydracarbazineHydracarbazine may increase the serotonergic activities of Escitalopram.Approved
HydrochlorothiazideEscitalopram may increase the hyponatremic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneHydrocodone may increase the serotonergic activities of Escitalopram.Approved, Illicit
HydroflumethiazideEscitalopram may increase the hyponatremic activities of Hydroflumethiazide.Approved
HydromorphoneHydromorphone may increase the serotonergic activities of Escitalopram.Approved, Illicit
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Escitalopram.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
IbutilideIbutilide may increase the QTc-prolonging activities of Escitalopram.Approved
IdelalisibThe serum concentration of Escitalopram can be increased when it is combined with Idelalisib.Approved
IloperidoneEscitalopram may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Escitalopram can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Escitalopram.Approved
IndalpineEscitalopram may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Escitalopram.Approved
IndinavirThe metabolism of Escitalopram can be decreased when combined with Indinavir.Approved
Insulin AspartEscitalopram may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEscitalopram may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEscitalopram may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEscitalopram may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEscitalopram may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEscitalopram may increase the hypoglycemic activities of Insulin Lispro.Approved
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Escitalopram.Approved
Ioflupane I-123Escitalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IproclozideIproclozide may increase the serotonergic activities of Escitalopram.Withdrawn
IproniazidIproniazid may increase the serotonergic activities of Escitalopram.Withdrawn
IsavuconazoniumThe metabolism of Escitalopram can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the serotonergic activities of Escitalopram.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
IsoniazidThe metabolism of Escitalopram can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Escitalopram.Approved
ItraconazoleThe metabolism of Escitalopram can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Escitalopram.Approved
IvacaftorThe serum concentration of Escitalopram can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Escitalopram.Approved
KetobemidoneKetobemidone may increase the serotonergic activities of Escitalopram.Approved
KetoconazoleThe metabolism of Escitalopram can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Escitalopram.Approved, Nutraceutical
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Escitalopram.Approved, Investigational
LanreotideEscitalopram may increase the hypoglycemic activities of Lanreotide.Approved
LapatinibLapatinib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
LenvatinibLenvatinib may increase the QTc-prolonging activities of Escitalopram.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Escitalopram.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Escitalopram.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Escitalopram.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Escitalopram.Approved
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the serotonergic activities of Escitalopram.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Escitalopram is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the serotonergic activities of Escitalopram.Approved
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Escitalopram.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram.Approved, Vet Approved
LinezolidLinezolid may increase the serotonergic activities of Escitalopram.Approved, Investigational
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Escitalopram.Approved
LiraglutideEscitalopram may increase the hypoglycemic activities of Liraglutide.Approved
LithiumLithium may increase the serotonergic activities of Escitalopram.Approved
LofentanilLofentanil may increase the serotonergic activities of Escitalopram.Illicit
LopinavirEscitalopram may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Escitalopram.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lorcaserin.Approved
LovastatinThe metabolism of Escitalopram can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Loxapine.Approved
Lu AA21004Escitalopram may increase the serotonergic activities of Lu AA21004.Investigational
LuliconazoleThe serum concentration of Escitalopram can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Escitalopram can be decreased when it is combined with Lumacaftor.Approved
LumefantrineEscitalopram may increase the QTc-prolonging activities of Lumefantrine.Approved
LumiracoxibEscitalopram may increase the antiplatelet activities of Lumiracoxib.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Lurasidone.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Escitalopram.Approved, Vet Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Escitalopram.Approved
MebanazineMebanazine may increase the serotonergic activities of Escitalopram.Withdrawn
MecaserminEscitalopram may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Escitalopram.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Escitalopram.Vet Approved
MefloquineMefloquine may increase the QTc-prolonging activities of Escitalopram.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Escitalopram.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.Approved
MetforminEscitalopram may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Escitalopram.Approved
Methadyl AcetateMethadyl Acetate may increase the serotonergic activities of Escitalopram.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Escitalopram.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Escitalopram.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Escitalopram.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.Approved
MethyclothiazideEscitalopram may increase the hyponatremic activities of Methyclothiazide.Approved
Methylene blueEscitalopram may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.Approved, Investigational
MetolazoneEscitalopram may increase the hyponatremic activities of Metolazone.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Escitalopram.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Escitalopram.Approved
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Escitalopram.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
MiglitolEscitalopram may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Escitalopram is combined with Milnacipran.Approved
MinaprineMinaprine may increase the serotonergic activities of Escitalopram.Approved
MirabegronMirabegron may increase the QTc-prolonging activities of Escitalopram.Approved
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Escitalopram.Approved
MitotaneThe serum concentration of Escitalopram can be decreased when it is combined with Mitotane.Approved
MoclobemideMoclobemide may increase the serotonergic activities of Escitalopram.Approved
ModafinilThe serum concentration of Escitalopram can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Escitalopram.Approved
MolindoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Molindone.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Escitalopram.Approved, Withdrawn
MorphineMorphine may increase the serotonergic activities of Escitalopram.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.Approved, Investigational
NabumetoneEscitalopram may increase the antiplatelet activities of Nabumetone.Approved
NafcillinThe serum concentration of Escitalopram can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may increase the serotonergic activities of Escitalopram.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Escitalopram.Approved, Investigational
NateglinideEscitalopram may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NefazodoneThe metabolism of Escitalopram can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Escitalopram can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Escitalopram can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Escitalopram can be increased when combined with Nevirapine.Approved
NialamideNialamide may increase the serotonergic activities of Escitalopram.Withdrawn
NicardipineNicardipine may increase the QTc-prolonging activities of Escitalopram.Approved
NilotinibEscitalopram may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Escitalopram.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Escitalopram.Approved
NormethadoneNormethadone may increase the serotonergic activities of Escitalopram.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.Approved
OctamoxinOctamoxin may increase the serotonergic activities of Escitalopram.Withdrawn
OctreotideOctreotide may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
OfloxacinOfloxacin may increase the QTc-prolonging activities of Escitalopram.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
OlaparibThe metabolism of Escitalopram can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Escitalopram.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.Approved
OmeprazoleThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Escitalopram.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Escitalopram.Investigational
OpiumOpium may increase the serotonergic activities of Escitalopram.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Escitalopram.Approved
OsanetantThe risk or severity of adverse effects can be increased when Escitalopram is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Escitalopram can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Oxetacaine is combined with Escitalopram.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Escitalopram.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram.Approved
OxycodoneOxycodone may increase the serotonergic activities of Escitalopram.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the serotonergic activities of Escitalopram.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
PalbociclibThe serum concentration of Escitalopram can be increased when it is combined with Palbociclib.Approved
PaliperidoneEscitalopram may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Escitalopram.Approved, Investigational
PanobinostatThe serum concentration of Escitalopram can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Escitalopram can be decreased when combined with Pantoprazole.Approved
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Escitalopram.Approved
ParecoxibEscitalopram may increase the antiplatelet activities of Parecoxib.Approved
PargylinePargyline may increase the serotonergic activities of Escitalopram.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Escitalopram.Approved
PazopanibPazopanib may increase the QTc-prolonging activities of Escitalopram.Approved
Peginterferon alfa-2bThe serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Escitalopram.Approved
PentazocinePentazocine may increase the serotonergic activities of Escitalopram.Approved, Vet Approved
PentobarbitalThe metabolism of Escitalopram can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Escitalopram.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Escitalopram.Investigational
PerflutrenPerflutren may increase the QTc-prolonging activities of Escitalopram.Approved
PerospironeThe risk or severity of adverse effects can be increased when Escitalopram is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Escitalopram.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Escitalopram.Approved
PhenelzinePhenelzine may increase the serotonergic activities of Escitalopram.Approved
PhenindioneEscitalopram may increase the anticoagulant activities of Phenindione.Approved
PheniprazinePheniprazine may increase the serotonergic activities of Escitalopram.Withdrawn
PhenobarbitalThe metabolism of Escitalopram can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Escitalopram.Approved
PhenoxypropazinePhenoxypropazine may increase the serotonergic activities of Escitalopram.Withdrawn
PhenprocoumonEscitalopram may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe metabolism of Escitalopram can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pimozide.Approved
PioglitazoneEscitalopram may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Pipotiazine.Approved
PiritramidePiritramide may increase the serotonergic activities of Escitalopram.Investigational
PirlindolePirlindole may increase the serotonergic activities of Escitalopram.Approved
PivhydrazinePivhydrazine may increase the serotonergic activities of Escitalopram.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Escitalopram.Approved
PolythiazideEscitalopram may increase the hyponatremic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.Approved
PosaconazoleThe metabolism of Escitalopram can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideEscitalopram may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Escitalopram.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Escitalopram.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Pregnanolone is combined with Escitalopram.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Escitalopram.Approved
PrimaquinePrimaquine may increase the QTc-prolonging activities of Escitalopram.Approved
PrimidoneThe metabolism of Escitalopram can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideProcainamide may increase the QTc-prolonging activities of Escitalopram.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Escitalopram.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Escitalopram.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.Approved, Vet Approved
PromazinePromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Escitalopram.Approved
PropafenonePropafenone may increase the QTc-prolonging activities of Escitalopram.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Escitalopram.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Escitalopram.Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Escitalopram.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Escitalopram is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Escitalopram.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Escitalopram.Approved, Illicit
QuetiapineEscitalopram may increase the QTc-prolonging activities of Quetiapine.Approved
QuinethazoneEscitalopram may increase the hyponatremic activities of Quinethazone.Approved
QuinidineQuinidine may increase the QTc-prolonging activities of Escitalopram.Approved
QuinineQuinine may increase the QTc-prolonging activities of Escitalopram.Approved
RacloprideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.Approved, Investigational
RanolazineRanolazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
RasagilineRasagiline may increase the serotonergic activities of Escitalopram.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Escitalopram.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Remoxipride.Approved, Withdrawn
RepaglinideEscitalopram may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Reserpine.Approved
RifabutinThe metabolism of Escitalopram can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Escitalopram can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Escitalopram can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Escitalopram.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Escitalopram.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Escitalopram is combined with Ritanserin.Investigational
RitonavirThe metabolism of Escitalopram can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Escitalopram.Approved
RofecoxibEscitalopram may increase the antiplatelet activities of Rofecoxib.Investigational, Withdrawn
RolapitantThe metabolism of Escitalopram can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Escitalopram.Vet Approved
RopiniroleThe metabolism of Escitalopram can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram.Approved
RosiglitazoneEscitalopram may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Escitalopram.Experimental
SafrazineSafrazine may increase the serotonergic activities of Escitalopram.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sage 547 is combined with Escitalopram.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Escitalopram.Approved
SaquinavirSaquinavir may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
SaxagliptinEscitalopram may increase the hypoglycemic activities of Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.Approved, Vet Approved
SelegilineSelegiline may increase the serotonergic activities of Escitalopram.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sertindole.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Escitalopram.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
SildenafilThe metabolism of Escitalopram can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Escitalopram can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Escitalopram.Approved
SitagliptinEscitalopram may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Escitalopram.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Escitalopram.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Escitalopram.Approved
St. John's WortThe serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Escitalopram can be increased when it is combined with Stiripentol.Approved
SufentanilSufentanil may increase the serotonergic activities of Escitalopram.Approved, Investigational
SulfadiazineEscitalopram may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Escitalopram.Approved
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Escitalopram.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Escitalopram.Approved, Investigational
TamoxifenTamoxifen may increase the QTc-prolonging activities of Escitalopram.Approved
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Escitalopram.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tapentadol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Escitalopram.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Escitalopram.Approved
TelaprevirThe serum concentration of Escitalopram can be decreased when it is combined with Telaprevir.Approved
TelavancinTelavancin may increase the QTc-prolonging activities of Escitalopram.Approved
TelithromycinTelithromycin may increase the QTc-prolonging activities of Escitalopram.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.Approved
TerbinafineThe metabolism of Escitalopram can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineTerbutaline may increase the QTc-prolonging activities of Escitalopram.Approved
TetrabenazineEscitalopram may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Escitalopram.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Escitalopram.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Escitalopram.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Escitalopram.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Escitalopram.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.Approved
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Escitalopram.Approved
TiaprideThe risk or severity of adverse effects can be increased when Escitalopram is combined with Tiapride.Investigational
TiclopidineThe metabolism of Escitalopram can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Escitalopram.Vet Approved
TipranavirThe metabolism of Escitalopram can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Escitalopram.Approved
TocilizumabThe serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.Approved
TolazamideEscitalopram may increase the hypoglycemic activities of Tolazamide.Approved
TolbutamideEscitalopram may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.Approved, Withdrawn
ToloxatoneToloxatone may increase the serotonergic activities of Escitalopram.Approved
TolterodineTolterodine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TopiramateThe metabolism of Escitalopram can be decreased when combined with Topiramate.Approved
ToremifeneToremifene may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TramadolEscitalopram may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the serotonergic activities of Escitalopram.Experimental
TranylcypromineTranylcypromine may increase the serotonergic activities of Escitalopram.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.Approved
TrichlormethiazideEscitalopram may increase the hyponatremic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Escitalopram.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.Approved, Vet Approved
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Escitalopram.Approved, Vet Approved
TropisetronTropisetron may increase the serotonergic activities of Escitalopram.Investigational
Uc1010The risk or severity of adverse effects can be increased when Uc1010 is combined with Escitalopram.Investigational
ValdecoxibEscitalopram may increase the antiplatelet activities of Valdecoxib.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Escitalopram.Approved, Investigational
VandetanibEscitalopram may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Escitalopram.Approved
VemurafenibEscitalopram may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Escitalopram.Approved
VerapamilThe metabolism of Escitalopram can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Escitalopram.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Escitalopram.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Escitalopram is combined with Vilazodone.Approved
VoriconazoleThe metabolism of Escitalopram can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Vortioxetine.Approved
WarfarinEscitalopram may increase the anticoagulant activities of Warfarin.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Escitalopram.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Escitalopram.Approved
ZimelidineEscitalopram may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the QTc-prolonging activities of Escitalopram.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Escitalopram.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Escitalopram.Approved, Investigational
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Escitalopram.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Escitalopram.Approved
ZotepineThe risk or severity of adverse effects can be increased when Escitalopram is combined with Zotepine.Approved
ZuclopenthixolEscitalopram may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals.
References
Synthesis Reference

Robert Dancer, “Escitalopram hydrobromide and a method for the preparation thereof.” U.S. Patent US20040167209, issued August 26, 2004.

US20040167209
General References
  1. Moore N, Verdoux H, Fantino B: Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005 May;20(3):131-7. [PubMed:15812262 ]
  2. Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M: A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006 Jul;22(7):1331-41. [PubMed:16834832 ]
  3. Bielski RJ, Ventura D, Chang CC: A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004 Sep;65(9):1190-6. [PubMed:15367045 ]
  4. Nierenberg AA, Greist JH, Mallinckrodt CH, Prakash A, Sambunaris A, Tollefson GD, Wohlreich MM: Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin. 2007 Feb;23(2):401-16. [PubMed:17288694 ]
  5. Chen F, Larsen MB, Sanchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005 Mar;15(2):193-8. [PubMed:15695064 ]
External Links
ATC CodesN06AB10
AHFS Codes
  • 28:16.04.20
PDB EntriesNot Available
FDA labelDownload (1.09 MB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9729
Caco-2 permeable+0.6099
P-glycoprotein substrateSubstrate0.7597
P-glycoprotein inhibitor INon-inhibitor0.6361
P-glycoprotein inhibitor IIInhibitor0.9789
Renal organic cation transporterInhibitor0.6993
CYP450 2C9 substrateNon-substrate0.8401
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.5054
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5223
Ames testNon AMES toxic0.7602
CarcinogenicityNon-carcinogens0.7452
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.9054 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7735
hERG inhibition (predictor II)Inhibitor0.8994
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
TabletOral5 mg
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
Tablet, orally disintegratingOral10 mg
Tablet, orally disintegratingOral20 mg
Tablet, coatedOral20 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
SolutionOral5 mg/5mL
TabletOral10 mg/1
TabletOral20 mg/1
TabletOral5 mg/1
Tablet, film coatedOral10 mg/21
Tablet, film coatedOral20 mg/21
Prices
Unit descriptionCostUnit
Lexapro 20 mg tablet3.71USD tablet
Lexapro 10 mg tablet3.55USD tablet
Lexapro 5 mg tablet3.4USD tablet
Lexapro 5 mg/5ml Solution0.72USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1339452 No1997-09-092014-09-09Canada
CA2373757 No2010-01-052020-07-07Canada
US6916941 Yes2003-02-122023-02-12Us
US7420069 Yes2003-02-122023-02-12Us
USRE34712 No1994-09-142011-09-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00588 mg/mLALOGPS
logP3.58ALOGPS
logP3.76ChemAxon
logS-4.7ALOGPS
pKa (Strongest Basic)9.78ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area36.26 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity94.02 m3·mol-1ChemAxon
Polarizability35.21 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylbutylamines. These are compounds containing a phenylbutylamine moiety, which consists of a phenyl group substituted at the fourth carbon by an butan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylbutylamines
Direct ParentPhenylbutylamines
Alternative Parents
Substituents
  • Phenylbutylamine
  • Benzonitrile
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Aryl halide
  • Aryl fluoride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Oxacycle
  • Organoheterocyclic compound
  • Nitrile
  • Carbonitrile
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
  • 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile (CHEBI:36791 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Owens MJ, Knight DL, Nemeroff CB: Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001 Sep 1;50(5):345-50. [PubMed:11543737 ]
  2. Owens JM, Knight DL, Nemeroff CB: [Second generation SSRIS: human monoamine transporter binding profile of escitalopram and R-fluoxetine]. Encephale. 2002 Jul-Aug;28(4):350-5. [PubMed:12232544 ]
  3. Burke WJ: Escitalopram. Expert Opin Investig Drugs. 2002 Oct;11(10):1477-86. [PubMed:12387707 ]
  4. Waugh J, Goa KL: Escitalopram : a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343-62. [PubMed:12665392 ]
  5. Sanchez C, Bergqvist PB, Brennum LT, Gupta S, Hogg S, Larsen A, Wiborg O: Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities. Psychopharmacology (Berl). 2003 Jun;167(4):353-62. Epub 2003 Apr 26. [PubMed:12719960 ]
  6. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  7. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]
  8. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sanchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett. 2009 Oct 25;462(3):207-12. doi: 10.1016/j.neulet.2009.07.030. Epub 2009 Jul 16. [PubMed:19616061 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Bareggi SR, Mundo E, Dell'Osso B, Altamura AC: The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opin Drug Metab Toxicol. 2007 Oct;3(5):741-53. [PubMed:17916059 ]
  2. Fabre V, Hamon M: [Mechanisms of action of antidepressants: new data from Escitalopram]. Encephale. 2003 May-Jun;29(3 Pt 1):259-65. [PubMed:12876551 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Baumann P: Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996 Dec;31(6):444-69. [PubMed:8968657 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 09, 2016 03:54